Green Critical Minerals Quotations Expand ASX Securities August 2025

Green Critical Minerals Limited has announced the listing of 300,000 fully paid ordinary securities on the Australian Securities Exchange as part of its efforts to strengthen its capital structure and enhance market presence. Meanwhile, Green Minerals AS is set to release its half-year 2025 financial results on August 7, with a live audiocast and Q&A session planned to discuss its progress in sustainable deep sea mining of key minerals and rare earth elements essential for the green energy transition. Mineralys Therapeutics, a clinical-stage biopharmaceutical company specializing in treatments for hypertension and related comorbidities, will report its Q2 2025 earnings on August 12, hosting a conference call and live webcast to review its financial performance and development pipeline, including its lead drug candidate lorundrostat. These corporate updates highlight active engagement by companies in critical minerals and biopharmaceutical sectors, reflecting ongoing strategic developments and transparency with investors. Both Green Minerals AS and Mineralys Therapeutics emphasize their roles in addressing significant industry challenges—sustainable mineral sourcing for clean energy and innovative medicinal therapies for cardiovascular and related conditions.